Progressed decisions centered on advancing our strategic partnerships and progressing our approach to commercialisation through our Governance committees (Management Committee [MC], Scientific Steering Committee [SSC] and Commercialisation Steering Committee [CSC]).
Engaged an IP/Corporate Lawyer to advise on becoming a legally incorporated company, with advantages for managing CAD Frontiers Program IP
Begun an “IP Stock take” focused on understanding the background IP of key academic partners in the CAD Frontier Program, as basis for preparing a commercialisation strategy
Worked with the Australian Cardiovascular Alliance (ACvA), BioPlatforms Australia and the Australian BioCommons to select Gen3 as the data platform to enable secure user-friendly data access to enable analysis of ‘virtual’ CAD cohorts.
Begun work to onboard CAD cohorts (Bioheat, AusDiab and FIELD) to the data platform.
Appointed a new Research Assistant and Clinical Trial Coordinator to our Kolling Institute Frontier team.
Met with scientific leads for each of the three CAD Frontiers research Cores (see previous issue), to begin ‘brainstorming’ a Stage 2 budget. More brainstorming to follow shortly, involving wider groups of partners.
Agreed to work with Allelica1 on innovative digital technologies centered on DMGV and CAD risk profiles
Begun work to expand the number of clinical settings in which iCoreLab’s imaging and data integration/analysis capabilities are being implemented
Engaged marketing company ‘The Monkeys’, to help with branding, and production of the Stage 2 application.